Lifeward Ltd. announced that President and CEO Mark Grant departed effective August 31, 2026, following a separation agreement. His unvested equity awards were forfeited, and he will serve as Senior Advisor through September 30, 2026, for a $40,000 consulting fee without cash severance. The Board appointed Josh Hexter as Interim CEO effective September 1, 2026; Hexter receives a monthly salary of NIS 100,000 plus benefits and will reduce his role at controlling shareholder Oramed Pharmaceuticals to approximately 5% of his time. Additionally, Rami Aviram was appointed CFO effective November 1, 2026, succeeding Almog Adar who departs September 30, 2026; Aviram receives a monthly salary of NIS 70,000 plus benefits. Lifeward Ltd. operates in the life sciences industry, developing medical devices and treatments.

Lifeward Ltd. appointed Yonason Greenwald and Haggai Zamir as Class III Directors on August 14, 2026, with terms expiring at the 2026 Annual Meeting of Shareholders. On August 20, 2026, Avraham Gabay was appointed to the Board and designated Chair, while Nadav Kidron resigned effective immediately due to no disagreement with company operations. The new directors will receive standard non-employee director compensation as disclosed in the March 18, 2026 Form 10-K. Lifeward Ltd. operates in the healthcare technology industry, providing digital health solutions and services.

Lifeward Ltd. reported second quarter 2026 financial results showing revenue increased 16% to $6.6 million, driven by stronger sales in Europe and higher U.S. unit shipments for AlterG products. The company strengthened its balance sheet with a proforma cash balance of approximately $11 million following a strategic financing closed on July 6, 2026, which provided up to $11.2 million in growth capital. Concurrently, the Board accepted the resignation of directors Robert J. Marshall Jr., Michael Swinford, and William Mark Sigsbee effective August 13, 2026. Chief Financial Officer Almog Adar announced his departure effective September 30, 2026, to assist with a transition to a successor. Lifeward Ltd. is a diversified biomedical innovation company focused on commercialized neurorehabilitation products and a biomedical pipeline.

Lifeward Ltd. entered into a securities purchase agreement with Oramed Pharmaceuticals Inc. and certain investors to issue $11,160,000 in senior secured convertible notes and accompanying warrants. The transaction consists of $5,580,000 in initial notes and warrants, which closed on July 6, 2026, and a second $5,580,000 tranche of notes and warrants contingent upon the company achieving a 150% increase in ReWalk unit sales or its stock price reaching $13.80 for ten consecutive trading days. The notes carry an 8.0% annual interest rate, increasing to 15.0% upon default, and feature an initial conversion price of $5.40 per share. The company also amended and restated existing notes and warrants to revise beneficial ownership and redemption provisions. Lifeward Ltd. is a medical technology company specializing in mobility solutions.